Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

TTNP Relative to the S&P 500

TTNP Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Titan Pharmaceuticals, Inc. (NASD:TTNP) seasonal charts above shows that a Buy Date of January 1 and a Sell Date of March 25 has resulted in a geometric average return of 9.5% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 11 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 109.5% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

To download TTNP seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: TTNP